• Afatinib in Gastric Cancer Assembloid Research

  2026-09-21

  Afatinib, also known as BIBW 2992, gives researchers an irreversible ErbB-family perturbation tool for comparing tumor organoids with patient-matched stromal assembloids. This workflow shows how to connect EGFR, HER2, and HER4 pathway biology with practical drug-response, resistance, and tumor–stroma assays.

• Mucocutaneous Candidiasis: Diagnosis and Treatment

  2026-09-21

  This 2009 guideline review organizes mucocutaneous candidiasis by clinical presentation and establishes direct microscopy as the decisive diagnostic test when Candida is suspected. Its practical contribution is a risk-based treatment framework that prioritizes topical imidazoles for cutaneous disease while reserving systemic therapy for nail, oral, extensive, recurrent, or deep infection.

• Estradiol Workflows for ER–Autophagy Studies

  2026-09-20

  Build reproducible 17 beta-estradiol assays that connect estrogen receptor signaling with autophagy, fibrosis, and tissue-protection readouts. This practical guide distinguishes receptor-specific effects from vehicle, timing, and flux artifacts across cardiovascular and renal research models.

• Praeruptorin A: From Mechanism to Translation

  2026-09-19

  Praeruptorin A is an angular pyranocoumarin compound with a distinctive translational profile spanning iron-dependent cell death, inflammation, tissue barrier protection, cardiomyopathy research, and tumor invasion. This article frames how researchers can convert its multi-pathway biology into better-controlled preclinical decisions.

• Coumestrol Drives Ferroptosis in RA Fibroblasts

  2026-09-18

  A 2026 study identifies a TRIM3–PMAIP1 regulatory axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. The findings connect mitochondrial protein stabilization with reduced synoviocyte proliferation and inflammatory cytokine production, while highlighting the need for validation in primary cells and in vivo models.

• Neuritin, ER Stress, and NF-κB After SAH

  2026-09-18

  A 2024 Brain Research study examines how neuritin limits early brain injury after subarachnoid hemorrhage by suppressing three endoplasmic-reticulum-stress-related inflammatory routes that converge on NF-κB. Its integrated model connects ER stress, neuroinflammation, and neuronal apoptosis, while suggesting experimental strategies for testing pathway convergence rather than treating NF-κB as an isolated endpoint.

• Tunicamycin for ER Stress Research

  2026-09-17

  Tunicamycin is a mechanistically direct N-glycosylation inhibitor for connecting glycoprotein processing defects with unfolded protein response signaling. This guide translates the compound into practical workflows for RAW264.7 macrophages, glioblastoma stress-resistance studies, and reproducible assay troubleshooting.

• Rex NADH/NAD+ Biosensor for Bacterial Redox

  2026-09-17

  Liu, Landick, and Raman developed a genetically encoded, ratiometric NADH/NAD+ biosensor by coupling the redox-responsive bacterial transcription factor Rex to an engineered promoter. The system enabled noninvasive comparison of bacterial redox states, revealed respiratory-chain and carbon-source effects, and supported enrichment of rare high-NADH mutants in pooled populations.

• Gefitinib (ZD1839) for EGFR Pathway Assays

  2026-09-16

  Gefitinib (ZD1839) converts EGFR biology into a controllable perturbation for cancer, skin-barrier, and drug-response experiments. This guide links dose planning, blue-light injury models, mechanistic readouts, and troubleshooting so researchers can distinguish pathway blockade from nonspecific toxicity.

• Tunicamycin for ER Stress: Applied Workflows

  2026-09-16

  Use Tunicamycin as a mechanistically defined N-glycosylation inhibitor to connect glycoprotein maturation defects with ER stress, UPR signaling, and inflammatory phenotypes. This guide translates glioblastoma ER-stress findings into practical RAW264.7 macrophage assays, comparative designs, and troubleshooting decisions.

• Afatinib in ErbB Signaling and Cancer Models

  2026-09-15

  Afatinib, also known as BIBW 2992, is an irreversible ErbB-family kinase inhibitor used to study EGFR, HER2, and HER4 signaling. Its covalent mechanism supports targeted therapy research, while patient-derived gastric cancer assembloids provide a physiologically relevant system for testing stromal effects on drug response.

• Erlotinib Workflows for EGFR Research

  2026-09-15

  Build reproducible EGFR phosphorylation, proliferation, and apoptosis assays with Erlotinib (NSC 718781). The workflow also shows how EGFR blockade can function as a mechanistic comparator when investigating SCUBE3-driven oncogenic signaling and tumor-cell resistance.

• Partial Aβ Reduction Preserves Synaptic Transmission

  2026-09-14

  Satir and colleagues tested whether moderate β-secretase inhibition could reduce amyloid beta secretion without disrupting neuronal communication. Using primary rat cortical cultures and optical electrophysiology, they found that reductions below approximately half of secreted Aβ were not associated with impaired synaptic transmission, whereas stronger inhibition reduced both Aβ secretion and neuronal activity.

• Machine Learning Discovery of Senolytics

  2026-09-14

  The reference study shows that cost-effective machine learning can identify senolytic compounds from small, heterogeneous collections of published screening data. Computational prioritization followed by cell-based validation identified ginkgetin, periplocin, and oleandrin as senolytics, illustrating a practical route for reducing early drug-discovery screening costs while preserving experimental validation.

• LIRP Gene Switches for Light-Controlled Gene Therapy

  2026-09-13

  The reference study presents a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates mammalian gene expression at translation, keeping transgene activity low in darkness and permitting expression under blue or ambient light. In mouse models, the switch supported controllable therapeutic programs for diet-induced obesity and retinal neovascular disease, illustrating how optical regulation can add reversibility and safety control to gene therapy.

8066 records 1/538 page Next 12345 下5页 Last page